CORE-010: MEDICINAL CHEMISTRY SHARED RESOURCE (MCSR) PROJECT SUMMARY / ABSTRACT The Medicinal Chemistry Shared Resource (MCSR) is critical to the OSUCCC drug development mission supporting preclinical studies leading to more rationale clinical trial designs and effective cancer therapies. Established during the last grant application as a developing shared resource, the MCSR is now being proposed as a formal shared resource. The MCSR's Senior Faculty Advisor is Dr. Ching-Shih Chen, a highly accomplished medicinal chemist, who established the MCSR as the director. The director of the MCSR is now Dr. Chad Bennett, a recent recruit, who is an experienced medicinal and process chemist with industry experience. The MCSR has three Specific Aims: 1) to custom-synthesize new agents to improve cancer therapeutics; 2) to synthesize agents for cancer researchers needing compounds that are not available; and, 3) lead optimization by conducting structure-activity relationship (SAR) analyses and structure-based design. To accomplish these aims, the MCSR integrates the expertise of multiple disciplines, including medicinal chemistry, process chemistry, computational chemistry, structural biology and molecular pharmacology. The MCSR is located in the 4th floor of Biomedical Research Tower, in close proximity to most OSUCCC investigators. Since 2011, when the MCSR was established, the MCSR has provided chemical synthesis services to 32 OSUCCC investigators, 9 investigators from other NCI-sponsored institutions, and has synthesized 33 compounds that were otherwise not available from commercial sources or were cost prohibitive. These agents have helped investigators to conduct proof-of-concept in vitro and/or in vivo preclinical experiments that have aided in a better understanding of cancer biology and led to rationale clinical trial development. The MCSR has contributed to 63 publications over the last grant period, 6 of which were in journals with an impact factor >10, and it has supported 6 NCI grants (not including services provided for 9 other NCI Cancer Centers). The future plans are to build a formal partnership with the OSUCCC's Drug Development Institute and to increase services for lead optimization. The MCSR leverages extensive institutional support, and seeks only 15.4% support from CCSG funds. The Medicinal Chemistry Shared Resource is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-41
Application #
9221255
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications